TQL-1055

TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21. It functions as a vaccine adjuvant, enhancing immune responses to co-administered antigens. Compared to natural QS-21, TQL-1055 offers improved tolerability and enables large-scale manufacturing due to its semi-synthetic production process using raw material from leaves and branches of the Quillaja saponaria tree. This design overcomes previous limitations of dose-limiting toxicity and supply constraints associated with natural saponins. In clinical studies, TQL-1055 has demonstrated favorable safety and tolerability profiles in healthy adults, with only mild or moderate local and systemic adverse events reported. It is being developed for use in vaccines against infectious diseases such as tuberculosis (TB) and hepatitis B (HBV), where it has shown strong immunogenicity in preclinical models[1][3][4][5][6][7].